SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)

DSpace Repository

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)

Author: Retz, Margitta; Bedke, Jens; Boegemann, Martin; Grimm, Marc-Oliver; Zimmermann, Uwe; Mueller, Lothar; Leiber, Christian; Teber, Dogu; Wirth, Manfred; Bolenz, Christian; van Alphen, Robbert; De Santis, Maria; Beeker, Aart; Lehmann, Jan; Indorf, Martin; Frank, Melanie; Bokemeyer, Carsten; Gschwend, Juergen E.
Tübinger Autor(en):
Bedke, Jens
Published in: European Journal of Cancer (2019), Bd. 107, S. 37-45
Verlagsangabe: Elsevier Sci Ltd
Language: English
Full text: http://dx.doi.org/10.1016/j.ejca.2018.11.001
ISSN: 1879-0852
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)